共 50 条
- [21] The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer PatientsCANCERS, 2022, 14 (23)Pawlowska, AnnaSkiba, WiktoriaSuszczyk, DorotaKurylo, WeronikaJakubowicz-Gil, JoannaPaduch, RomanWertel, Iwona
- [22] Identification of secreted PD-L1 variants as a decoy of PD-L1 blockade antibody mediating the therapeutic resistanceMOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)Gong, BoKiyotani, KazumaSakata, SeijiTakahashi, KenNagano, SeijiKumehara, ShunBaba, SatokoBesse, BenjaminYanagitani, NorikoFriboulet, LucNishio, MakotoTakeuchi, KengoKawamoto, HiroshiFujita, NaoyaKatayama, Ryohei
- [23] PD-L1 blockade enhances anti-tumor efficacy of NK cellsONCOIMMUNOLOGY, 2018, 7 (11):Oyer, Jeremiah L.Gitto, Sarah B.Altomare, Deborah A.Copik, Alicja J.
- [24] Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancerONCOIMMUNOLOGY, 2016, 5 (06):Nakhle, JessicaPierron, ValerieBauchet, Anne-LaurePlas, PascaleThiongane, AmathMeyer-Losic, FlorenceSchmidlin, Fabien
- [25] PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regressionJOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (02): : 580 - 588Tang, HaidongLiang, YongAnders, Robert A.Taube, Janis M.Qiu, XiangyanMulgaonkar, AditiLiu, XinHarrington, Susan M.Guo, JingyaXin, YangchunXiong, YahongNham, KienSilvers, WilliamHao, GuiyangSun, XiankaiChen, MingyiHannan, RaquibulQiao, JianDong, HaidongPeng, HuaFu, Yang-Xin
- [26] LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint BlockadeJOURNAL OF IMMUNOLOGY, 2022, 209 (03): : 510 - 525Yoo, Kyung JinJohannes, KellseyGonzalez, Louis E.Patel, ArpitaShuptrine, Casey W.Opheim, ZacharyLenz, KarenCampbell, KristenThuy-Ai NguyenMiriyala, JayalakshmiSmith, ConnorMcGuire, AshlynTsai, Yi-HsuanRangwala, Fatimade Silva, SureshSchreiber, Taylor H.Fromm, George
- [27] Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumorMOLECULAR THERAPY, 2025, 33 (02)Oh, WonkyungKim, Alyssa Min JungDhawan, DeepikaKnapp, Deborah W.Lim, Seung-Oe
- [28] Blockade of Myeloid Suppressor Cells Overcomes the Anti-PD-1/PD-L1 Resistance in KRAS-Driven and LKB1-Deficient NSCLCJOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S15 - S15Li, R.Salehi-Rad, R.Momcilovic, M.Lim, R.Ong, S.Huang, Z.Tran, L.Zhe, J.Paul, M.Teitell, M.Minna, J.Krysan, K.Shackelford, D.Liu, B.Dubinett, S.
- [29] Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapyNature Cancer, 2020, 1 : 264 - 264Gabriel Abril-RodriguezDavis Y. TorrejonWei LiuJesse M. ZaretskyTheodore S. NowickiJennifer TsoiCristina Puig-SausIgnacio Baselga-CarreteroEgmidio MedinaMichael J. QuistAlejandro J. GarciaWilliam SenapedisErkan BalogluAnusha KalbasiGardenia Cheung-LauBeata Berent-MaozBegoña Comin-AnduixSiwen Hu-LieskovanCun-Yu WangCatherine S. GrassoAntoni Ribas
- [30] Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 InteractionsJOURNAL OF IMMUNOTHERAPY, 2015, 38 (03) : 96 - 106Lussier, Danielle M.O'Neill, LaurenNieves, Lizbeth M.McAfee, Megan S.Holechek, Susan A.Collins, Andrea W.Dickman, PaulJacobsen, JeffreyHingorani, PoojaBlattman, Joseph N.